Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) SVP Santiago Arroyo sold 2,531 shares of the company’s stock in a transaction that occurred on Monday, April 29th. The shares were sold at an average price of $15.00, for a total value of $37,965.00. Following the completion of the transaction, the senior vice president now directly owns 19,272 shares of the company’s stock, valued at $289,080. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Santiago Arroyo also recently made the following trade(s):
- On Tuesday, April 9th, Santiago Arroyo sold 8,119 shares of Momenta Pharmaceuticals stock. The shares were sold at an average price of $15.00, for a total value of $121,785.00.
- On Thursday, February 14th, Santiago Arroyo sold 2,671 shares of Momenta Pharmaceuticals stock. The shares were sold at an average price of $13.10, for a total value of $34,990.10.
Momenta Pharmaceuticals stock opened at $14.04 on Friday. Momenta Pharmaceuticals, Inc. has a 12 month low of $9.55 and a 12 month high of $32.20. The company has a market capitalization of $1.38 billion, a P/E ratio of -6.92 and a beta of 2.18.
Several research firms have recently issued reports on MNTA. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $16.00 target price on shares of Momenta Pharmaceuticals in a report on Friday, February 22nd. Stifel Nicolaus reaffirmed a “buy” rating and issued a $29.00 target price on shares of Momenta Pharmaceuticals in a report on Friday, February 22nd. Zacks Investment Research raised Momenta Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $17.00 target price for the company in a report on Saturday, April 27th. BTIG Research began coverage on Momenta Pharmaceuticals in a report on Monday, March 18th. They issued a “neutral” rating and a $14.15 target price for the company. Finally, BidaskClub raised Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, March 29th. Six research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Momenta Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $22.23.
Institutional investors have recently bought and sold shares of the stock. Oregon Public Employees Retirement Fund purchased a new position in Momenta Pharmaceuticals in the fourth quarter valued at approximately $37,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Momenta Pharmaceuticals by 41.4% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,880 shares of the biotechnology company’s stock valued at $65,000 after purchasing an additional 1,723 shares during the last quarter. Quantamental Technologies LLC purchased a new position in Momenta Pharmaceuticals in the first quarter valued at approximately $68,000. Smith Asset Management Group LP purchased a new position in Momenta Pharmaceuticals in the fourth quarter valued at approximately $99,000. Finally, Amalgamated Bank purchased a new position in Momenta Pharmaceuticals in the fourth quarter valued at approximately $136,000. Institutional investors and hedge funds own 96.82% of the company’s stock.
Momenta Pharmaceuticals Company Profile
Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy.
Further Reading: Dividend
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.